Innate Pharma S.A. (IPHA)

NASDAQ: IPHA · Real-Time Price · USD
2.037
+0.087 (4.44%)
Oct 8, 2025, 11:52 AM EDT - Market open
4.44%
Market Cap186.12M
Revenue (ttm)14.84M
Net Income (ttm)-54.08M
Shares Out 92.16M
EPS (ttm)-0.64
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume149
Open2.010
Previous Close1.950
Day's Range2.010 - 2.010
52-Week Range1.290 - 3.511
Beta0.91
AnalystsHold
Price Target2.00 (-1.79%)
Earnings DateSep 17, 2025

About IPHA

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 17, 2019
Employees 181
Stock Exchange NASDAQ
Ticker Symbol IPHA
Full Company Profile

Financial Performance

In 2024, Innate Pharma's revenue was 20.12 million, a decrease of -67.36% compared to the previous year's 61.64 million. Losses were -49.47 million, 553.5% more than in 2023.

Financial numbers in EUR Financial Statements

Analyst Summary

According to 2 analysts, the average rating for IPHA stock is "Hold." The 12-month stock price target is $2.0, which is a decrease of -1.79% from the latest price.

Price Target
$2.0
(-1.79% downside)
Analyst Consensus: Hold
Stock Forecasts

News

Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q2 2025 Earnings Call September 17, 2025 8:00 AM EDT Company Participants Stéphanie Cornen Jonathan Dickinson - CEO & Director Yannis Morel - Executive VP & COO Sonia...

21 days ago - Seeking Alpha

Innate Pharma Reports First Half 2025 Business Update and Financial Results

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma Reports First Half 2025 Business Update And Financial Results.

21 days ago - Business Wire

Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma announces its participation in the 25th edition of the European Midcap Event.

23 days ago - Business Wire

Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma announces conference call and webcast for first half 2025 financial results and business update.

4 weeks ago - Business Wire

Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference

MARSEILLE, France--(BUSINESS WIRE)-- #IRConference--Innate Pharma announces its participation in BTIG virtual biotechnology conference.

2 months ago - Business Wire

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

MARSEILLE, France--(BUSINESS WIRE)-- #InvestorRelations--Innate Pharma announces its participation in H.C. Wainwright and Wolfe Research Healthcare Conferences.

4 months ago - Business Wire

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of preclinical data for ...

4 months ago - Business Wire

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

MARSEILLE, France--(BUSINESS WIRE)-- #IRConferences--Innate Pharma announces its participation in upcoming investor conferences.

4 months ago - Business Wire

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of long-term fol...

4 months ago - Business Wire

Outcome of Innate Pharma's 2025 Annual General Meeting

MARSEILLE, France--(BUSINESS WIRE)-- #AG--Outcome of Innate Pharma's 2025 Annual General Meeting.

4 months ago - Business Wire

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate's drugs i...

5 months ago - Business Wire

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH6501, its A...

5 months ago - Business Wire

Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Corporate Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - Chief Executive Officer...

5 months ago - Seeking Alpha

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the q...

5 months ago - Business Wire

Innate Pharma announces conference call and webcast for Q1 2025 business update

MARSEILLE, France--(BUSINESS WIRE)-- #innatepharma--Innate Pharma announces conference call and webcast for Q1 2025 business update.

5 months ago - Business Wire

Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2024 Universal Registra...

5 months ago - Business Wire

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

MARSEILLE, France--(BUSINESS WIRE)-- #AACR--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today shared new preclinical data for IPH4502, its novel a...

5 months ago - Business Wire

Innate Pharma Announces €15M Investment by Sanofi

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces a €14,999,998.59 capital increase subscri...

5 months ago - Business Wire

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announce review of their January 2016 Research Coll...

6 months ago - Business Wire

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma proposes to its shareholders to transform its corporate governance structure into a board of directors and to change its composition.

6 months ago - Business Wire

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to hold its Annual General Meeting of shareholders on May 22, 2025.

6 months ago - Business Wire

Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in the 2025 Stifel Virtual Targeted Oncology Forum.

6 months ago - Business Wire

Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2024 Earnings Conference Call March 27, 2025 9:00 AM ET Company Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - CEO Yannis Morel - COO ...

6 months ago - Seeking Alpha

Innate Pharma Reports Full Year 2024 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the y...

6 months ago - Business Wire

Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting

MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH4502, its nov...

7 months ago - Business Wire